Anastrozole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Early Breast Cancer
Conditions
Early Breast Cancer
Trial Timeline
Jun 1, 2006 → Jan 1, 2009
NCT ID
NCT00323479About Anastrozole
Anastrozole is a approved stage product being developed by AstraZeneca for Early Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00323479. Target conditions include Early Breast Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Early Breast Cancer were approved
Approved (0) Terminated (1) Active (19)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00936442 | Pre-clinical | Completed |
| NCT00660244 | Pre-clinical | Completed |
| NCT00562458 | Pre-clinical | Completed |
| NCT00555867 | Pre-clinical | Terminated |
| NCT00323479 | Approved | Completed |
| NCT00544986 | Approved | Completed |
| NCT00638391 | Pre-clinical | Completed |
| NCT00256217 | Phase 2 | Completed |
| NCT00295620 | Phase 3 | Completed |
| NCT00437853 | Pre-clinical | Completed |
| NCT00637182 | Phase 3 | Completed |
| NCT00300508 | Phase 3 | Completed |
Competing Products
20 competing products in Early Breast Cancer